ATE374244T1 - Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden - Google Patents

Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden

Info

Publication number
ATE374244T1
ATE374244T1 AT01910649T AT01910649T ATE374244T1 AT E374244 T1 ATE374244 T1 AT E374244T1 AT 01910649 T AT01910649 T AT 01910649T AT 01910649 T AT01910649 T AT 01910649T AT E374244 T1 ATE374244 T1 AT E374244T1
Authority
AT
Austria
Prior art keywords
methods
ctl
cytotoxic
identification
dendritic cell
Prior art date
Application number
AT01910649T
Other languages
German (de)
English (en)
Inventor
Jianlin Gong
Donald Kufe
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE374244T1 publication Critical patent/ATE374244T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01910649T 2000-02-11 2001-02-12 Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden ATE374244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18182200P 2000-02-11 2000-02-11
US18468700P 2000-02-24 2000-02-24

Publications (1)

Publication Number Publication Date
ATE374244T1 true ATE374244T1 (de) 2007-10-15

Family

ID=26877549

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01910649T ATE374244T1 (de) 2000-02-11 2001-02-12 Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden

Country Status (7)

Country Link
EP (1) EP1263928B1 (https=)
JP (1) JP5054875B2 (https=)
AT (1) ATE374244T1 (https=)
AU (1) AU3823601A (https=)
CA (1) CA2399432C (https=)
DE (1) DE60130634T2 (https=)
WO (1) WO2001059073A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2848255B1 (en) 2001-02-20 2017-08-23 Janssen Pharmaceuticals, Inc. Artificial Drosophila antigen presenting cell for preparing CD8 cell suspension for use in the treatment of cancer
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
CA2558382A1 (en) * 2004-03-02 2005-09-15 Tsuneya Ohno Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
EP3375868A1 (en) * 2007-11-08 2018-09-19 Dana Farber Cancer Institute, Inc. Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28
EP3628322A1 (en) * 2013-03-01 2020-04-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Cd8+ t cells that also express pd-1 and/or tim-3 for the treatment of cancer
CN105112369A (zh) * 2015-08-25 2015-12-02 北京康爱瑞浩生物科技股份有限公司 具有持续抗肿瘤活性的ctl细胞制剂及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634750T2 (de) * 1995-03-31 2006-02-23 Université Libre de Bruxelles DENDRITENZELLEN/TUMORZELLEN Hybirde ZUR INDUKTION EINER ANTI-TUMOR ANTWORT
DE69839215T2 (de) * 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride
WO2000057705A1 (en) * 1999-03-31 2000-10-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens

Also Published As

Publication number Publication date
AU3823601A (en) 2001-08-20
DE60130634D1 (de) 2007-11-08
EP1263928B1 (en) 2007-09-26
WO2001059073A9 (en) 2002-10-24
DE60130634T2 (de) 2008-07-17
WO2001059073A2 (en) 2001-08-16
EP1263928A1 (en) 2002-12-11
JP5054875B2 (ja) 2012-10-24
CA2399432C (en) 2012-04-10
CA2399432A1 (en) 2001-08-16
JP2003521936A (ja) 2003-07-22
WO2001059073A3 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
ATE231917T1 (de) Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
EP2316476A3 (en) Antigenic peptides derived from telomerase
ES2132395T3 (es) Especificidad lisosomica de inmunogenos.
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
ATE432085T1 (de) Stimulationsfaktor für dendriten
BR9712988A (pt) Imunoterapia do câncer usando células tumorais combinadas com mistura de linfócitos
EP1363660A4 (en) HIGHER MOLECULAR VACCINE BASED ON AUTOMPLICATIVE RNA, SUICIDE DNA OR UNDNA DNA VECTOR, WHICH LINKS ANTIGEN WITH A POLYPEPTIDE WHICH PROMOTES THE PRESENTATION OF THE ANTIGEN
RU2009130954A (ru) Применение белков теплового шока для улучшения терапевтического эффекта невакционного лечебного воздействия
WO2006014579A3 (en) Enhancing class i antigen presentation with synthetic sequences
EA200300640A1 (ru) Фармацевтические композиции, усиливающие иммуногенность антигенов со слабой иммуногенностью
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
ATE374244T1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
PT1272633E (pt) Composições e métodos para imunoterapia baseada em células dendríticas
BR0205083A (pt) Polipeptìdeo isolado, composição farmacêutica, proteìna de fusão, polinucleotìdeo isolado, vetor de expressão, célula hospedeira recombinante e métodos de produzir um polipeptìdeo, de detectar a presença da expressão de gene em uma amostra biológica, de expandir células monocìticas ou progenitores de células de monócitos e de estimular uma resposta imune em um mamìfero exposto a um antìgeno ou patógeno
ATE134195T1 (de) Peptidfragmente von hiv
ES2234287T3 (es) Vacunas que comprenden proteinas de choque termico (hsp) inducidas por citoquinas.
ATE412763T1 (de) Antikörper-abhängige vergrösserung der alphavirus-infektvität
DE60043070D1 (de) Proteine-abgabe durch polare epithelzellen schichte
Arcuri et al. Synergistic effect of gene‐electro transfer and adjuvant cytokines in increasing the potency of hepatitis C virus genetic vaccination
AU2004200711B2 (en) Vaccine Comprising Cytokine-Induced Heat Shock Proteins (HSP)
ES8801958A1 (es) Un procedimiento para la determinacion de virus de sida

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties